La stabilisation des taux d’intérêt et de l’inflation devrait créer un climat plus favorable à l’investissement et permettre aux sociétés immobilières de poursuivre la mise en œuvre de leur feuille de route tout en faisant preuve de prudence. Dans ce contexte, le commerce et la logistique nous semblent les mieux positionnés et nous privilégions CTP, Merlin Properties, Shurgard, URW, VGP comme les plus à même d’exécuter leur stratégie de croissance. Nous relevons notre opinion à Surperformance su...
With stabilising interest rates and inflation creating a more favourable climate for investment, the stocks in our coverage universe should be able to continue to implement their roadmaps, while remaining cautious. On this basis, we think retail and logistics are the best positioned, and see CTP, Merlin Properties, Shurgard, URW and VGP as the best placed to execute their growth strategies. We are upgrading WDP, Safestore and Instone, to Outperform, downgrading Big Yellow, Colonial-SFL, INEA, L...
VGP NV: kondigt de resultaten aan van haar aanbod tot aankoop in cash inzake diens uitstaande 500.000.000 EUR 1,625% vaste rente groene obligaties met 17 januari 2027 als vervaldatum (ISIN: BE6332786449) NIET VOOR VRIJGAVE, PUBLICATIE OF VERSPREIDING IN OF NAAR OF AAN ENIGE PERSOON GEVESTIGD OF WOONACHTIG IN DE VERENIGDE STATEN VAN AMERIKA, DIENS TERRITORIA EN BEZITTINGEN (INCLUSIEF PUERTO RICO, DE AMERIKAANSE MAAGDENEILANDEN, GUAM, AMERIKAANS SAMOA, HET EILAND WAKE EN DE NOORDELIJKE MARIANA EILANDEN), ENIGE STAAT VAN DE VERENIGDE STATEN VAN AMERIKA OF HET DISTRICT VAN COLUMBIA (DE “VERENIG...
VGP NV: announces results of its cash tender offer for its outstanding EUR 500,000,000 1.625 per cent. fixed rate green bonds due 17 January 2027 (ISIN: BE6332786449) NOT FOR RELEASE, PUBLICATION OR DISTRIBUTION IN OR INTO OR TO ANY PERSON LOCATED OR RESIDENT IN THE UNITED STATES OF AMERICA, ITS TERRITORIES AND POSSESSIONS (INCLUDING PUERTO RICO, THE U.S. VIRGIN ISLANDS, GUAM, AMERICAN SAMOA, WAKE ISLAND AND THE NORTHERN MARIANA ISLANDS), ANY STATE OF THE UNITED STATES OF AMERICA OR THE DISTRICT OF COLUMBIA (THE “UNITED STATES”) OR TO ANY U.S. PERSON (AS DEFINED IN REGULATION S OF THE UNITE...
DEME takes delivery of its second new wind turbine installation vessel Norse Energi DEME has taken delivery of its second new wind turbine installation vessel, Norse Energi, today at the CIMC Raffles Shipyard. As the sister vessel of the recently delivered Norse Wind, Norse Energi is purpose‑built to install the next generation of large-scale offshore wind turbines. Featuring advanced technology, exceptional lifting and loading capabilities, and sustainable design features, both vessels will help reinforce DEME’s position at the forefront of offshore wind installation. Attachments ...
DEME neemt tweede nieuwe installatieschip voor windturbines Norse Energi in ontvangst DEME heeft vandaag op de CIMC Raffles-scheepswerf zijn tweede nieuwe installatieschip voor windturbines, Norse Energi, in ontvangst genomen. Als zusterschip van het recent opgeleverde Norse Wind is Norse Energi speciaal gebouwd om de volgende generatie grootschalige offshore windturbines te installeren. Met geavanceerde technologie, uitzonderlijke hijs- en laadcapaciteiten en een duurzaam ontwerp zullen beide schepen DEME’s positie als koploper in installatie van offshorewind verder verstevigen. Bijla...
European real estate rebounded in 2025, signalling positive momentum after two difficult years. In 2026, we expect investors to adapt to a new, normalised environment with recalibrated profitability that should drive transaction activity. This comes alongside a normalisation of rents (on the back of lower inflation) – a slowdown that will be notable but largely expected. We see a company's ability (and willingness) to pursue EPS-accretive investments and being active in capital recycling opportu...
Onward enters 2026 with increased commercial momentum following FDA clearance for ARC-EX home use in SCI patients in November 2025, which expands access beyond clinics and is expected to accelerate adoption. Meanwhile, the company is advancing its implantable program, with ARC-IM interim data from the pivotal Empower BP trial in SCI patients with blood pressure instability expected in 2H26—an important catalyst that could accelerate development timelines. We roll over our model to 2026, adjustin...
Unfortunately, this report is not available for the investor type or country you selected.
Report is subscription only.
Thank you, your report is ready.
Thank you, your report is ready.